… (EGFR) is a receptor tyrosine kinase which belongs to the EGFR family, consisting of four
members: EGFR, … the tyrosine kinase activity of EGFR via homo- or heterodimerization with …

… underlying EGFR-TKIs resistance in lung cancer could … The present review features insights
into current updates on the … and acquired resistance against EGFR-TKIs in lung cancer. In …

… In approximately 30% of the NSCLC patients whose tumors harbor epidermal growth factor
receptor (EGFR) activating mutation, EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib …

… of the successes in targeting oncogene addiction in cancer and the role of tumor-… tyrosine
kinase inhibitor, which was granted full FDA approval in March 2017 based on targeting EGFR …

… harboring an activating EGFR mutation (mut) and treated with a first-generation EGFR TKI
develop a secondary gatekeeper T790M mut. EGF816 is an irreversible EGFR TKI that is …

… adenocarcinoma and in smokers, are associated with resistance to EGFR tyrosine kinase
inhibitors (TKI). EGFR gene mutations are not found in tumors with K-RAS gene mutations. …

… Currently available EGFR/HER2 tyrosine kinase inhibitors (TKIs) exhibit many adverse …
of breast cancer and its therapy. It emphasizes the currently marketed drugs for EGFR, HER2, …

… EGFR TKIs, binding competitively and reversibly to the ATP-binding site of the EGFR
tyrosine … in outcome for NSCLC patients with activating EGFR mutations (L858R and Del19). …

… The availability of several EGFR tyrosine kinase inhibitors (TKIs) for the treatment of EGFR
mutation-… Nowadays, clinicians have the choice of three generations of EGFR tyrosine kinase …

… as having EGFR-mutant cancers following progression on their initial EGFR inhibitor,
including the impact of identified resistance mechanisms where applicable. EGFR indicates …